系统性硬化 - - 诊断和管理方面的最新进展
William J Kerrigan1, Alistair C Church1,2, Ariane L Herrick3,4
1Scottish Pulmonary Vascular Unit, Golden Jubilee National Hospital, NHS Golden Jubilee, Glasgow, UK.
British journal of hospital medicine (London, England : 2005)
|December 24, 2025
概括
系统性硬化症的治疗进展显著,早期扩散性疾病,数字,肺部疾病和肺动脉高血压的新选择. 目前正在进行的研究有望在管理这种复杂的结缔组织疾病方面取得进一步进展.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 肺部病理学 肺部病理学
背景情况:
- 系统性硬化症是一种严重的多系统连接组织疾病.
- 它具有显著的发病率和死亡率.
- 最近的治疗进展是相当大的.
研究的目的:
- 为了提供系统性硬化症的概述.
- 突出最近在管理特定并发症方面的进展.
- 专注于早期扩散性皮肤病,数字血管病,间歇性肺病和肺动脉高血压.
主要方法:
- 审查最近的科学文献和临床试验数据.
- 综合有关新兴和成熟疗法的信息.
- 专注于基于证据的治疗策略.
主要成果:
- 自主造血干细胞移植是选择早期扩散性系统性硬化症患者的一个选择.
- 固酶5型抑制剂和博森坦可以改善数字.
- 对治疗间歇性肺病的免疫抑制剂和抗纤维素药物的理解得到了改善.
- 早期组合疗法越来越多地用于肺动脉高血压.
结论:
- 在治疗系统性硬化症方面取得了实质性的进展.
- 目前的治疗策略为关键并发症提供了更好的结果.
- 目前正在进行的临床试验预计将产生进一步的治疗创新.
相关概念视频
Nephrotic Syndrome II : Assessment and Medical Management
179
IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document...
179
Atherosclerosis III: Management
291
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
291
Rheumatic Heart Disease III: Medical Management
263
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
263
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
439
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
439
Asthma-IV: Diagnostic and Management
3.0K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.0K
Cystic Fibrosis: Management
438
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
438


